発作の世界市場レポート 2025

発作市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で54億9,000万米ドルに成長します。予測期間の成長は、神経障害の影響を受けやすい高齢者人口の拡大、発作治療薬の研究開発投資の増加、世界のヘルスケア支出の増加、てんかん治療薬の需要拡大、発作性疾患の罹患率の上昇などに起因すると考えられます。この期間の主な動向としては、発作検出・監視装置の進歩、医薬品承認・償還プロセスの進展、個別化発作治療のための遺伝子研究の躍進、遠隔モニタリングのためのデジタルヘルスソリューションの採用、てんかん治療薬の継続的な技術革新などが挙げられます。

外傷性脳損傷（TBI）の有病率の増加は、発作市場の大幅な成長を牽引すると予想されます。TBIは、頭部への打撃、衝撃、貫通損傷などの外力によって生じ、高速衝突や脇見運転による交通事故の増加が、より深刻な頭部損傷の原因となっています。発作は、しばしばTBIの早期指標となり、医師が脳の損傷をより効果的に診断・管理するのに役立ちます。例えば、2023年10月、サウスダコタ州保健局（SDDOH）の報告書によると、2022年、サウスダコタ州の年齢調整後のTBI関連死亡率は米国で9番目に高く、10万人当たり26.4人でした。さらに、米国神経外科学会は、米国では年間170万人から380万人のTBIが発生していると推定しています。このような外傷性脳損傷の有病率の上昇が、発作市場の成長を促進しています。

発作市場の主要企業は、アクセシビリティと患者のアドヒアランスを向上させるため、頬側フィルムなどの革新的な治療に注力しています。頬内フィルムは薄く、溶解可能なストリップで、頬の内側（頬粘膜）に貼ることで投与され、薬物は血流に直接吸収されます。例えば、2024年12月、米国を拠点とするAquestive Therapeutics Inc.は、Libervant（ジアゼパム）頬側フィルムの希少疾病用医薬品の独占承認を米国FDAから取得しました。同剤は、てんかん発作群を有する2～5歳の小児患者を対象としています。Libervantは、従来のジアゼパム製剤に代わる非侵襲的で投与しやすい製剤であり、頬粘膜からの吸収をより確実にします。この年齢層で承認された最初で唯一の経口投与ジアゼパムフィルムとして、Libervantは介護者の利便性を向上させ、患者のコンプライアンスを高めることを目指しています。今回の承認は、経口フィルムベースのてんかん治療薬の開発におけるAquestive社の地位をさらに強化するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界発作PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の発作市場：成長率分析
• 世界の発作市場の実績：規模と成長, 2019-2024
• 世界の発作市場の予測：規模と成長, 2024-2029, 2034F
• 世界発作総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の発作市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代の抗てんかん薬
• 第二世代抗てんかん薬
• 第三世代抗てんかん薬
• 世界の発作市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 非経口
• 外用
• 世界の発作市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 独立系薬局
• オンライン薬局
• 世界の発作市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• 在宅ケア環境
• その他のエンドユーザー
• 世界の発作市場、第一世代抗てんかん薬のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェニトイン
• カルバマゼピン
• バルプロ酸
• フェノバルビタール
• プリミドン
• エトスクシミド
• 世界の発作市場、第二世代抗てんかん薬のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラモトリギン
• レベチラセタム
• トピラマート
• オキシカルバゼピン
• ゾニサミド
• ガバペンチン
• プレガバリン
• 世界の発作市場、第三世代抗てんかん薬のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラコサミド
• ペランパネル
• ブリバラセタム
• エスリカルバゼピン
• セノバマテ

第7章 地域別・国別分析

• 世界の発作市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の発作市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 発作市場：競合情勢
• 発作市場：企業プロファイル
  • Johnson & Johnson Service Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• UCB S.A.
• Eisai Co. Ltd.
• H. Lundbeck A/S
• Zydus Lifesciences Limited
• SK Biopharmaceuticals Co. Ltd.
• Neurocrine Biosciences Inc.
• Supernus Pharmaceuticals Inc.
• Taro Pharmaceutical Industries Ltd.
• Marinus Pharmaceuticals Inc.
• Eton Pharmaceuticals Inc.
• Sunovion Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 発作市場2029：新たな機会を提供する国
• 発作市場2029：新たな機会を提供するセグメント
• 発作市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Seizures are sudden, uncontrolled electrical activities in the brain that can cause changes in movement, behavior, sensation, or awareness. They result from abnormal neuronal activity and can be triggered by conditions such as epilepsy, head injuries, infections, or other medical issues.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types used to treat seizures are first-generation, second-generation, and third-generation anti-epileptics. First-generation anti-epileptic drugs (AEDs) are the initial class of medications developed for epilepsy treatment. These drugs can be administered through various routes, including oral, parenteral, and topical methods. They are distributed through multiple channels, such as hospital pharmacies, independent pharmacies, and online pharmacies, and are utilized by several end-users, including hospitals, clinics, ambulatory surgical centers, homecare settings, and others.

The seizures market research report is one of a series of new reports from The Business Research Company that provides seizures market statistics, including the seizures industry global market size, regional shares, competitors with the seizures market share, detailed seizures market segments, market trends, and opportunities, and any further data you may need to thrive in the seizures industry. This seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The seizures market size has grown strongly in recent years. It will grow from$3.20 billion in 2024 to $4.35 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to the rising prevalence of epilepsy and seizure disorders, greater awareness and higher diagnosis rates, expanding research and development efforts for neurological conditions, increased government and non-profit initiatives aimed at epilepsy awareness, and the growing geriatric population.

The seizures market size is expected to see strong growth in the next few years. It will grow to$5.49 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the expanding geriatric population vulnerable to neurological disorders, increased investments in R&D for seizure therapeutics, rising global healthcare expenditure, growing demand for epilepsy medications, and a higher incidence of seizure disorders. Key trends during this period include advancements in seizure detection and monitoring devices, progress in drug approvals and reimbursement processes, breakthroughs in genetic research for personalized seizure treatments, the adoption of digital health solutions for remote monitoring, and ongoing innovations in epilepsy medications.

The increasing prevalence of traumatic brain injuries (TBI) is expected to drive significant growth in the seizures market. TBIs result from external forces, such as blows, jolts, or penetrating injuries to the head, and the rise in road accidents-due to high-speed collisions and distracted driving-has contributed to more severe head injuries. Seizures often serve as an early indicator of TBIs, helping doctors diagnose and manage brain damage more effectively. For example, in October 2023, a report from the South Dakota Department of Health (SDDOH) indicated that in 2022, South Dakota had the 9th highest age-adjusted TBI-related death rate in the U.S. at 26.4 per 100,000. Additionally, the American Association of Neurological Surgeons estimates that between 1.7 million and 3.8 million TBIs occur annually in the U.S. This rising prevalence of traumatic brain injuries is driving the growth of the seizures market.

Leading companies in the seizures market are focusing on innovative treatments such as buccal films to improve accessibility and patient adherence. Buccal films are thin, dissolvable strips that are administered by placing them on the inner cheek (buccal mucosa), where the drug is absorbed directly into the bloodstream. For instance, in December 2024, U.S.-based Aquestive Therapeutics Inc. received U.S. FDA approval for orphan drug exclusivity for Libervant (diazepam) buccal film. This drug is intended for pediatric patients aged two to five with seizure clusters. Libervant offers a non-invasive, easy-to-administer alternative to traditional diazepam delivery methods, ensuring faster absorption through the buccal mucosa. As the first and only orally administered diazepam film approved for this age group, Libervant aims to improve convenience for caregivers and enhance patient compliance. This approval further strengthens Aquestive's position in advancing oral film-based epilepsy therapies.

In March 2022, Belgium-based UCB Pharma acquired U.S.-based Zogenix Inc. for $1.9 billion. With this acquisition, UCB aims to expand its neurology portfolio and enhance treatment options for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. Zogenix is known for developing therapies for rare and serious central nervous system (CNS) disorders, helping UCB strengthen its presence in the epilepsy treatment market.

Major players in the seizures market are Johnson & Johnson Service Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., and Sunovion Pharmaceuticals Inc.

North America was the largest region in the seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in seizures report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The seizures market consists of sales of neurostimulation devices, wearable seizure detection devices, and medical cannabis products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Seizures Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on seizures market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for seizures ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The seizures market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: First Generation Anti-Epileptics; Second Generation Anti-Epileptics; Third Generation Anti-Epileptics
• 2) By Route Of Administration: Oral; Parenteral; Topical
• 3) By Distribution Channel: Hospitals Pharmacies; Independent Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals And Clinics; Ambulatory Surgical Centers; Homecare Settings; Other End-Users
• Subsegments:
• 1) By First Generation Anti-Epileptics: Phenytoin; Carbamazepine; Valproate; Phenobarbital; Primidone; Ethosuximide
• 2) By Second Generation Anti-Epileptics: Lamotrigine; Levetiracetam; Topiramate; Oxcarbazepine; Zonisamide; Gabapentin; Pregabalin
• 3) By Third Generation Anti-Epileptics: Lacosamide; Perampanel; Brivaracetam; Eslicarbazepine; Cenobamate
• Companies Mentioned: Johnson & Johnson Service Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Seizures Market Characteristics

3. Seizures Market Trends And Strategies

4. Seizures Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Seizures Growth Analysis And Strategic Analysis Framework

• 5.1. Global Seizures PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Seizures Market Growth Rate Analysis
• 5.4. Global Seizures Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Seizures Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Seizures Total Addressable Market (TAM)

6. Seizures Market Segmentation

• 6.1. Global Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First Generation Anti-Epileptics
• Second Generation Anti-Epileptics
• Third Generation Anti-Epileptics
• 6.2. Global Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• 6.3. Global Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Independent Pharmacies
• Online Pharmacies
• 6.4. Global Seizures Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Other End-Users
• 6.5. Global Seizures Market, Sub-Segmentation Of First Generation Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenytoin
• Carbamazepine
• Valproate
• Phenobarbital
• Primidone
• Ethosuximide
• 6.6. Global Seizures Market, Sub-Segmentation Of Second Generation Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lamotrigine
• Levetiracetam
• Topiramate
• Oxcarbazepine
• Zonisamide
• Gabapentin
• Pregabalin
• 6.7. Global Seizures Market, Sub-Segmentation Of Third Generation Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lacosamide
• Perampanel
• Brivaracetam
• Eslicarbazepine
• Cenobamate

7. Seizures Market Regional And Country Analysis

• 7.1. Global Seizures Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Seizures Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Seizures Market

• 8.1. Asia-Pacific Seizures Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Seizures Market

• 9.1. China Seizures Market Overview
• 9.2. China Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Seizures Market

• 10.1. India Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Seizures Market

• 11.1. Japan Seizures Market Overview
• 11.2. Japan Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Seizures Market

• 12.1. Australia Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Seizures Market

• 13.1. Indonesia Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Seizures Market

• 14.1. South Korea Seizures Market Overview
• 14.2. South Korea Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Seizures Market

• 15.1. Western Europe Seizures Market Overview
• 15.2. Western Europe Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Seizures Market

• 16.1. UK Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Seizures Market

• 17.1. Germany Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Seizures Market

• 18.1. France Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Seizures Market

• 19.1. Italy Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Seizures Market

• 20.1. Spain Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Seizures Market

• 21.1. Eastern Europe Seizures Market Overview
• 21.2. Eastern Europe Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Seizures Market

• 22.1. Russia Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Seizures Market

• 23.1. North America Seizures Market Overview
• 23.2. North America Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Seizures Market

• 24.1. USA Seizures Market Overview
• 24.2. USA Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Seizures Market

• 25.1. Canada Seizures Market Overview
• 25.2. Canada Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Seizures Market

• 26.1. South America Seizures Market Overview
• 26.2. South America Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Seizures Market

• 27.1. Brazil Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Seizures Market

• 28.1. Middle East Seizures Market Overview
• 28.2. Middle East Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Seizures Market

• 29.1. Africa Seizures Market Overview
• 29.2. Africa Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Seizures Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Seizures Market Competitive Landscape And Company Profiles

• 30.1. Seizures Market Competitive Landscape
• 30.2. Seizures Market Company Profiles
  • 30.2.1. Johnson & Johnson Service Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Seizures Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Viatris Inc.
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Bausch Health Companies Inc.
• 31.5. UCB S.A.
• 31.6. Eisai Co. Ltd.
• 31.7. H. Lundbeck A/S
• 31.8. Zydus Lifesciences Limited
• 31.9. SK Biopharmaceuticals Co. Ltd.
• 31.10. Neurocrine Biosciences Inc.
• 31.11. Supernus Pharmaceuticals Inc.
• 31.12. Taro Pharmaceutical Industries Ltd.
• 31.13. Marinus Pharmaceuticals Inc.
• 31.14. Eton Pharmaceuticals Inc.
• 31.15. Sunovion Pharmaceuticals Inc.

32. Global Seizures Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Seizures Market

34. Recent Developments In The Seizures Market

35. Seizures Market High Potential Countries, Segments and Strategies

• 35.1 Seizures Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Seizures Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Seizures Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34963_Seizures_GMR_2025